[{"id":"87bcd5d7-65b9-43a1-8517-f0ede1fe83cf","acronym":"NEUTHREE","url":"https://clinicaltrials.gov/study/NCT05949333","created_at":"2023-07-20T15:09:13.325Z","updated_at":"2024-07-02T16:35:17.796Z","phase":"Phase 4","brief_title":"Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy","source_id_and_acronym":"NCT05949333 - NEUTHREE","lead_sponsor":"Eunseong Medical Foundation Good GANG-AN HOSPITAL","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Rolvedon (eflapegrastim-xnst)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/07/2023","start_date":" 11/07/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-02-23"}]